Granted Patent B2

US 12,623,011 · App. 17/938,418 · Granted May 12, 2026

Inventors: Ian Crosbie (London, GB); Andreas Wirth (Simbach am Inn, DE); Oliver Goedje (Strasslach, DE)

Assignee: DSRCo BV

A61M1/28A61K9/0019A61K9/08A61K31/7004A61K31/716A61K33/14A61M1/287A61M27/002A61M31/002A61P7/08A61L2/0047A61L2202/21A61M2205/18A61M2205/3317A61M2205/3337A61M2205/3344A61M2205/3368A61M2205/3379A61M2205/3569A61M2205/3576A61M2205/502A61M2205/52A61M2205/587A61M2205/6009A61M2205/70A61M2205/8206A61M2205/8243A61M2209/086A61M2209/088A61M2210/1017A61M2210/1085

Abstract

Claims (32)

1 . A system for use with a direct sodium removal (DSR) solution for conducting direct sodium removal therapy in a patient, the system comprising:

an infusate configured to be introduced into a peritoneal cavity, the infusate comprising a solution having a sodium content less than 35 meq/L and (i) from 0.5 to 50 grams dextrose per 100 ml of aqueous solution, (ii) from 0.5 to 50 grams icodextrin/dextrin per 100 ml of aqueous solution, and (iii) purified water;

an analyte sensor configured to output a signal indicative of an analyte concentration associated with the infusate introduced into the peritoneal cavity; and

a processor coupled to the analyte sensor and configured to receive the signal indicative of the analyte concentration.

2 . The system of claim 1 , further comprising an implantable pump, wherein the processor is configured to cause the implantable pump to move fluid from the peritoneal cavity responsive either to the output of the analyte sensor or after expiration of a predetermined dwell time.

3 . The system of claim 2 , wherein the implantable pump further comprises a transceiver, a battery, an inlet port, and an outlet port.

4 . The system of claim 3 , further comprising an external charging and communications system for periodically charging the battery and conducting bi-directional data communication via the transceiver.

5 . The system of claim 4 , wherein the external charging and communications system inductively transfers energy to the implantable pump.

6 . The system of claim 2 , further comprising:

a peritoneal catheter comprising a first end configured to be disposed in the peritoneal cavity of the patient and a second end configured to be coupled to the implantable pump; and

a bladder catheter comprising a first end configured to be coupled to the implantable pump and a second end configured to be disposed in a urinary bladder.

7 . The system of claim 6 , wherein the analyte sensor measures a concentration of the analyte within at least one of: the implantable pump, the peritoneal catheter, the bladder catheter, or the peritoneal cavity.

8 . The system of claim 4 , further comprising a monitoring and control system configured to transfer data to the implantable pump via the external charging and communications system.

9 . The system of claim 2 , wherein the implantable pump comprises a gear pump.

10 . The system of claim 2 , wherein the processor is configured to cause the implantable pump to transfer, or cease transfer of, fluid from the peritoneal cavity when the output of the analyte sensor equals or exceeds a predetermined value.

11 . The system of claim 2 , wherein the processor is configured to cause the implantable pump to transfer, or cease transfer of, fluid from the peritoneal cavity when the output of the analyte sensor equals or falls below a predetermined value.

12 . The system of claim 2 , wherein the processor is configured to compute an amount of analyte removed from the peritoneal cavity by operation of the implantable pump.

13 . The system of claim 2 , further comprising a sensor configured to monitor pressure in a bladder, wherein the processor configured to interrupt transfer of fluid by the implantable pump from the peritoneal cavity to the bladder if the pressure in the bladder exceeds a threshold value.

14 . The system of claim 2 , further comprising a sensor configured to monitor pressure in the peritoneal cavity, wherein the processor further is configured to cease transfer of fluid by the implantable pump from the peritoneal cavity to a bladder if the pressure in the peritoneal cavity falls below a preset limit value.

15 . The system of claim 1 , wherein the analyte sensor is configured to monitor sodium ion concentration or electrical conductivity.

16 . The system of claim 1 , wherein the analyte sensor is configured to monitor a concentration of dextrose or icodextrin/dextrin in fluid in the peritoneal cavity.

17 . The system of claim 1 , wherein the solution further comprises urea or from 0.5 to 50 grams of high molecular weight glucose polymer per 100 ml of aqueous solution or both.

18 . The system of claim 1 , wherein the processor is configured to estimate an amount of sodium transferred from the peritoneal cavity using the output of the analyte sensor.

19 . A system for use with a direct sodium removal (DSR) solution for conducting direct sodium removal therapy in a patient, the system comprising:

an infusate configured to be introduced into a peritoneal cavity, the infusate being a solution with a sodium content less than 35 meq/L and consisting of 0.5 to 50 grams dextrose per 100 ml of aqueous solution, 0.5 to 50 grams icodextrin/dextrin per 100 ml of aqueous solution, and purified water;

an analyte sensor configured to output a signal indicative of an analyte concentration associated with the infusate introduced into the peritoneal cavity; and

a processor coupled to the analyte sensor and configured to receive the signal indicative of the analyte concentration.

20 . A method of performing direct sodium removal (DSR) therapy to remove excess sodium from a patient to reduce fluid overload, the method comprising:

introducing an infusate into a peritoneal cavity, the infusate comprising a solution having a sodium content less than 35 meq/L and (i) from 0.5 to 50 grams dextrose per 100 ml of aqueous solution, (ii) from 0.5 to 50 grams icodextrin/dextrin per 100 ml of aqueous solution, and (iii) purified water;

monitoring analyte concentration associated with the infusate introduced into the peritoneal cavity using an analyte sensor; and

receiving an output from the analyte sensor indicative of the analyte concentration.

21 . The method of claim 20 , further comprising pumping fluid from the peritoneal cavity responsive either to the output of the analyte sensor or after expiration of a predetermined dwell time.

Assignments (3)

Continuity (5)

References Cited (400)